BCDA - BioCardia, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.8600
+0.3400 (+22.37%)
At close: 04:00PM EDT
1.8400 -0.02 (-1.08%)
After hours: 07:19PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Relative Strength Index (RSI)

Relative Strength Index (RSI)

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close1.5200
Open1.5300
Bid1.7900 x 1200
Ask1.9600 x 800
Day's Range1.5300 - 1.9500
52 Week Range1.2300 - 2.6000
Volume56,198
Avg. Volume28,271
Market Cap37.608M
Beta (5Y Monthly)1.02
PE Ratio (TTM)N/A
EPS (TTM)-0.8000
Earnings DateAug 08, 2023 - Aug 14, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for BCDA

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    BioCardia Announces Timing of the Next Data Safety Monitoring Board Meeting for the CardiAMP Cell Therapy in Heart Failure Pivotal Study

    SUNNYVALE, Calif., May 23, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases today announced that the next Data Safety Monitoring Board (DSMB) meeting for the CardiAMP Cell Therapy Trial for Heart Failure is scheduled to take place on July 12th. The Company expects the FDA’s response to its adaptive statistical analysis plan supplement early to mid-June and anticipates approva

  • Simply Wall St.

    BioCardia First Quarter 2023 Earnings: EPS Beats Expectations, Revenues Lag

    BioCardia ( NASDAQ:BCDA ) First Quarter 2023 Results Key Financial Results Revenue: US$64.0k (up 6.7% from 1Q 2022...

  • Zacks

    BioCardia, Inc. (BCDA) Reports Q1 Loss, Misses Revenue Estimates

    BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of -30.77% and 81.18%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    BioCardia Reports First Quarter 2023 Business Highlights and Financial Results

    SUNNYVALE, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reports financial results for the first quarter of 2023 and filed its quarterly report on Form 10-Q for the three months ended March 31, 2023 with the Securities and Exchange Commission. The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights

  • GlobeNewswire

    BioCardia Announces US Patent on Bone Marrow Derived Neurokinin-1 Receptor Positive (NK1R+) Mesenchymal Stem Cells for Therapeutic Applications

    SUNNYVALE, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces that the United States Patent Office has granted Patent Number 11,642,377: titled, “ Bone Marrow Derived Neurokinin-1 Receptor Positive (NK1R+) Mesenchymal Stem Cells for Therapeutic Applications”, with a patent term that will expire in 2039. The patent specification details methods f

  • GlobeNewswire

    BioCardia to Host Q1 2023 Financial Results and Corporate Update Conference Call on May 10, 2023

    SUNNYVALE, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will report its financial results for the three months ended March 31, 2023 and provide a corporate update by conference call on Wednesday, May 10, 2023 at 4:30 PM ET. Following management’s formal remarks, there will be a question-and-answer session. Participants can register for t

  • GlobeNewswire

    BioCardia Presentations at Next Generation Cardiovascular Drug Development Summit Now Available

    SUNNYVALE, Calif., April 28, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases has made available two presentations from the “Next Generation Cardiovascular Drug Development Summit on Executing Cell and Gene Therapy for Cardiac Regeneration” which took place this week on April 26-27, 2023 in Boston, MA. This inaugural summit was intended to delve into the understanding of gene

  • GlobeNewswire

    BioCardia Announces Issuance of Two Patents Related to Technology That Guides Interventional Therapies

    SUNNYVALE, Calif., April 04, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the issuance of two patent grants related to enabling technologies for delivery of its investigational autologous and allogeneic cell therapies. The United States Patent Office issued BioCardia Patent Number 11,716,859, entitled “Multi-Directional Steerable Catheter,” with a patent

  • Insider Monkey

    BioCardia, Inc. (NASDAQ:BCDA) Q4 2022 Earnings Call Transcript

    BioCardia, Inc. (NASDAQ:BCDA) Q4 2022 Earnings Call Transcript March 29, 2023 Operator: Ladies and gentlemen, thank you for standing by. Good afternoon, and welcome to the BioCardia 2022 Yearend Conference Call. At this time, all participants are in a listen-only mode. I would now like to turn the conference over to of BioCardia Investor Relations. […]

  • Simply Wall St.

    We're Keeping An Eye On BioCardia's (NASDAQ:BCDA) Cash Burn Rate

    We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

  • GlobeNewswire

    BioCardia Reports Fourth Quarter and Full Year 2022 Business Highlights and Financial Results

    SUNNYVALE, Calif., March 29, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the year ended December 31, 2022 and filed its annual report on Form 10-K for the year ended December 31, 2022 with the Securities and Exchange Commission. The Company will also hold an update conference call at 4:30 PM ET today in which it will discuss business

  • GlobeNewswire

    BioCardia to Host 2022 Financial Results and Corporate Update Conference Call on March 29, 2023

    SUNNYVALE, Calif., March 16, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will report its financial results for the year ended December 31, 2022 and provide a corporate update conference call on Wednesday, March 29, 2023 at 4:30 PM ET. Following management’s formal remarks, there will be a question-and-answer session. Participants can register for the c

  • Benzinga

    BioCardia Outlines Detailed Cell Therapy Data From Heart Failure Study

    BioCardia Inc (NASDAQ: BCDA) presented detailed echocardiography data from the roll-in cohort of the Phase 3 CardiAMP Cell Therapy Heart Failure Trial. The echocardiography results from baseline through one and two years showed a more than doubling in the number of heart segments functioning normally and restoring function to 30% of previously non-functioning segments. This data expands upon what was previously presented at the Heart Failure Society of America annual meeting last fall. In this s

  • GlobeNewswire

    Positive Echocardiography Data from BioCardia Phase III CardiAMP Cell Therapy Heart Failure Trial Presented at American College of Cardiology Annual Meeting

    New Data from Roll-in Cohort of Trial Shows Progression of Patients from Baseline through One and Two Years Results Suggest CardiAMP Cell Therapy May Have Ability to Restore and Maintain Heart Function to Previously Non-Functioning Areas of the Heart Up to Two Years After Treatment SUNNYVALE, Calif., March 06, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announces that det

  • GlobeNewswire

    BioCardia and CellProthera Enhance Collaboration for Development of ProtheraCytes™ for the Treatment of Acute Myocardial Infarction in Europe and Potential Early Access for Patients

    SUNNYVALE, Calif. and MULHOUSE, France, Feb. 01, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, and CellProthera, a private developer of cell-based therapies to repair ischemic tissues, today announce an amendment to their Clinical Research Supply and Support Agreement. The amendment extends the long-term partnership between both organizations. The agreement relates to Cell

  • Simply Wall St.

    Shareholders in BioCardia (NASDAQ:BCDA) are in the red if they invested five years ago

    While it may not be enough for some shareholders, we think it is good to see the BioCardia, Inc. ( NASDAQ:BCDA ) share...

  • GlobeNewswire

    BioCardia Letter to Shareholders

    SUNNYVALE, Calif., Dec. 22, 2022 (GLOBE NEWSWIRE) -- BioCardia, Inc. (Nasdaq: BCDA), a clinical-stage developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases issued the following letter to shareholders: Dear Shareholders,BioCardia is now advancing four novel cell therapies, with three focused on heart disease, a leading cause of death and reduced quality of life globally. The Phase III trial of our lead therapy - CardiAMP® autologous cell th

  • Simply Wall St.

    Insider Buying: The BioCardia, Inc. (NASDAQ:BCDA) Independent Director Just Bought 14% More Shares

    Potential BioCardia, Inc. ( NASDAQ:BCDA ) shareholders may wish to note that the Independent Director, Simon Stertzer...

  • GlobeNewswire

    BioCardia Announces $3.6 Million Private Placement of Common Stock

    SUNNYVALE, Calif., Dec. 15, 2022 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that it has entered into a Securities Purchase and Registration Rights Agreement (the “Purchase Agreement”) relating to a private placement with certain new and existing qualified institutional buyers, institutional accredited investors and certain directors and office

  • Business Wire

    BioCardia Announces FDA Approval of IND Application for Allogeneic NK1R+ Human Mesenchymal Stem Cells for Ischemic Heart Failure

    SUNNYVALE, Calif., December 06, 2022--The FDA approves BioCardia's IND application to start a Phase I/II clinical trial of its NK1R+ allogeneic mesenchymal cell therapy for heart failure.

  • Zacks

    BioCardia, Inc. (BCDA) Reports Q3 Loss, Tops Revenue Estimates

    BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of 26.09% and 6%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    BioCardia Reports Third Quarter 2022 Business Highlights and Financial Results

    SUNNYVALE, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reports financial results for the third quarter of 2022 and filed its quarterly report on Form 10-Q for the three and nine months ended September 30, 2022 with the United States Securities and Exchange Commission (SEC). The Company will also hold an update conference call today at 4:30 PM ET. F

  • Zacks

    BioCardia, Inc. (BCDA) Upgraded to Buy: Here's What You Should Know

    BioCardia, Inc. (BCDA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

  • GlobeNewswire

    BioCardia to Host Q3 2022 Financial Results and Corporate Update Conference Call on November 9, 2022

    SUNNYVALE, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will report its financial results for the three and nine months ended September 30, 2022 and provide a corporate update by conference call on Wednesday, November 9, 2022 at 4:30 PM ET. Following management’s formal remarks, there will be a question-and-answer session. Participants

  • Benzinga

    BioCardia's Heart Failure Cell Therapy Shows 100% Survival At Two Years

    BioCardia Inc (NASDAQ: BCDA) announced data from its CardiAMP Cell Therapy for Heart Failure pivotal trial. "The two-year outcomes for patients with heart failure receiving the investigational CardiAMP Cell Therapy in the roll-in cohort showed clinical improvement with 100% survival over two years. These outcomes surpassed our expectations in terms of patient benefit across prespecified primary and secondary endpoints," said Peter Altman, BioCardia's President & CEO. "While this smaller cohort i